ATE435239T1 - Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen - Google Patents

Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen

Info

Publication number
ATE435239T1
ATE435239T1 AT03716836T AT03716836T ATE435239T1 AT E435239 T1 ATE435239 T1 AT E435239T1 AT 03716836 T AT03716836 T AT 03716836T AT 03716836 T AT03716836 T AT 03716836T AT E435239 T1 ATE435239 T1 AT E435239T1
Authority
AT
Austria
Prior art keywords
antibodies
relates
methods
compositions
interleukin
Prior art date
Application number
AT03716836T
Other languages
English (en)
Inventor
Scott Greenfeder
Jose Corvalan
Original Assignee
Schering Corp
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Abgenix Inc filed Critical Schering Corp
Application granted granted Critical
Publication of ATE435239T1 publication Critical patent/ATE435239T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
AT03716836T 2002-03-29 2003-03-27 Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen ATE435239T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36904402P 2002-03-29 2002-03-29
PCT/US2003/009260 WO2003085089A2 (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Publications (1)

Publication Number Publication Date
ATE435239T1 true ATE435239T1 (de) 2009-07-15

Family

ID=28791919

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716836T ATE435239T1 (de) 2002-03-29 2003-03-27 Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen

Country Status (16)

Country Link
US (2) US7141653B2 (de)
EP (1) EP1527100B1 (de)
JP (2) JP2005530490A (de)
CN (1) CN1326879C (de)
AT (1) ATE435239T1 (de)
AU (1) AU2003220525A1 (de)
CA (1) CA2479927C (de)
CY (1) CY1109423T1 (de)
DE (1) DE60328195D1 (de)
DK (1) DK1527100T3 (de)
ES (1) ES2327830T3 (de)
HK (1) HK1070907A1 (de)
MX (1) MXPA04009418A (de)
PT (1) PT1527100E (de)
SI (1) SI1527100T1 (de)
WO (1) WO2003085089A2 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1527100B1 (de) * 2002-03-29 2009-07-01 Schering Corporation Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
CA2505994A1 (en) 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2005047324A2 (en) * 2003-11-10 2005-05-26 Schering Corp ANTI-INTERLEUKIN ANTIBODY-10
WO2005068503A2 (en) 2004-01-07 2005-07-28 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
US20070173462A1 (en) * 2004-05-14 2007-07-26 Optimer Pharmaceuticals, Inc. Treatment of diseases associated with the use of antibiotics
KR101206318B1 (ko) 2004-10-28 2012-11-29 교와 핫꼬 기린 가부시키가이샤 자궁 내막증 치료제
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
EP1913027B1 (de) * 2005-07-28 2015-03-04 Novartis AG M-csf-spezifische monoklonale antikörper und anwendungen davon
WO2007016240A2 (en) * 2005-07-28 2007-02-08 Novartis Ag Use of antibody to m-csf
EP1945240B1 (de) 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Zusammensetzungen mit rezeptor-assoziierten protein (rap) varianten, die für cr-haltige proteine spezifisch sind und ihre verwendungen
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
WO2007070979A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Chimeric antibodies with part new world primate binding regions
JP5259423B2 (ja) 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド ドメイン抗体構築物
EP2010569A4 (de) 2006-03-20 2009-09-09 Xoma Technology Ltd Für gastrin spezifische humane antikörper, materialien und methoden
US20080038258A1 (en) * 2006-07-21 2008-02-14 Amgen Inc. Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making
JP4781929B2 (ja) 2006-07-25 2011-09-28 富士通株式会社 電子機器
JP4842040B2 (ja) 2006-07-25 2011-12-21 富士通株式会社 電子機器
JP2008027370A (ja) 2006-07-25 2008-02-07 Fujitsu Ltd 電子機器
JP5148079B2 (ja) 2006-07-25 2013-02-20 富士通株式会社 液冷ユニット用熱交換器および液冷ユニット並びに電子機器
CA2659820A1 (en) * 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
AU2007285855B2 (en) 2006-08-18 2013-03-07 Novartis Ag PRLR-specific antibody and uses thereof
WO2008036899A2 (en) * 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
US20100150948A1 (en) * 2006-10-24 2010-06-17 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
CN101687032A (zh) 2006-12-07 2010-03-31 诺瓦提斯公司 抗ephb3的拮抗剂抗体
EP2094306A2 (de) 2006-12-20 2009-09-02 XOMA Technology Ltd. Behandlung von il-1-beta-bedingten erkrankungen
TW201206954A (en) 2007-02-02 2012-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
SG177941A1 (en) 2007-04-03 2012-02-28 Oxyrane Uk Ltd Glycosylation of molecules
SI2152290T1 (sl) * 2007-04-30 2014-09-30 Glaxosmithkline Llc Postopki za dajanje anti-IL-5 protiteles
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
NO2188313T3 (de) * 2007-08-21 2018-03-31
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
EP2247618B1 (de) 2008-01-25 2014-06-11 Amgen, Inc Ferroportin-antikörper und anwendungsverfahren
BRPI0907135B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
CN102026660A (zh) * 2008-03-28 2011-04-20 葛兰素史密斯克莱有限责任公司 治疗方法
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
US8128932B2 (en) * 2009-08-17 2012-03-06 Shanghai Aosaiersi Biotech Co., Ltd. Anti-VEGFR monoclonal antibody, method of making and uses thereof
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
EP3187877A1 (de) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening-verfahren
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CA2781240A1 (en) 2009-11-19 2011-05-26 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
EP2526193A1 (de) 2010-01-21 2012-11-28 Oxyrane UK Limited Verfahren und zusammensetzungen zur anzeige eines polypeptids auf einer hefezellfläche
CA2812872C (en) 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
KR101983572B1 (ko) 2010-09-29 2019-05-29 옥시레인 유케이 리미티드 만노스-1-포스포-6-만노스 결합의 캡핑제거 및 인산화 n-글리칸의 탈만노실이 가능한 만노시다제 및 당단백질의 활용을 통한 포유류 세포의 촉진방법
KR101941514B1 (ko) * 2010-12-22 2019-01-23 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 개선된 반감기를 가지는 변형된 항체
EP2709662B1 (de) 2011-05-20 2019-07-31 AlderBio Holdings LLC Verwendung von anti-cgrp- oder anti-cgrp-r-antikörpern oder antikörperfragmenten zur behandlung oder prävention chronischer und akuter formen von diarrhöe
DK2710039T3 (en) 2011-05-20 2019-04-01 Alderbio Holdings Llc ANTI-CGRP COMPOSITIONS AND APPLICATION THEREOF
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
MY192843A (en) 2011-06-03 2022-09-12 Xoma Technology Ltd Antibodies specific for tgf-beta
US9345763B2 (en) 2011-06-23 2016-05-24 Children's Hospital Medical Center Methods of treating allergic inflammatory conditions by administering an anti-cadherin-like 26-based therapeutic
JP6320300B2 (ja) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 座瘡を治療するための方法
ES2886123T3 (es) 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
CN104379162B (zh) 2012-03-15 2017-03-15 奥克西雷恩英国有限公司 用于治疗蓬佩氏病的方法和材料
AR092177A1 (es) 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
US20190178879A1 (en) * 2012-08-23 2019-06-13 Stemcell Technologies Canada Inc. Compositions and methods for rapid and reversible biomolecular labeling
EP2906599B1 (de) * 2012-10-12 2019-07-17 Agency For Science, Technology And Research Optimierte schwerketten- und leichtketten-signalpeptide zur herstellung rekombinanter antikörpertherapeutika
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
MX2016002870A (es) 2013-09-05 2017-02-23 Amgen Inc Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
MX2016011132A (es) 2014-02-28 2016-12-08 Regeneron Pharma Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
RU2758608C2 (ru) 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
CN108136006A (zh) 2015-08-06 2018-06-08 佐马美国有限公司 针对胰岛素受体的抗体片段和其治疗低血糖的用途
US10821094B2 (en) 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
KR102462039B1 (ko) 2016-09-01 2022-11-02 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
US20190218284A1 (en) * 2016-09-01 2019-07-18 The Regents Of The University Of Colorado A Body Corporate Methods of treating eosinophilic gastrointestinal diseases
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
CA3038679A1 (en) 2016-09-28 2018-04-05 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
TW202332696A (zh) 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
CN110267986B (zh) 2016-12-23 2023-05-09 赛福伦有限责任公司 抗il-5抗体
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US20200332344A1 (en) * 2017-05-12 2020-10-22 The Regents Of The University Of California Treating and detecting dysbiosis
WO2018226339A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MX2020003034A (es) * 2017-09-29 2020-07-22 Jiangsu Hengrui Medicine Co Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
MX2020004467A (es) 2017-10-30 2020-10-22 Sanofi Biotechnology Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CN109942706A (zh) 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
AU2018394940A1 (en) * 2017-12-29 2020-08-13 Cornell University Gene therapy for eosinohilic disorders
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
EP3896085A4 (de) * 2018-12-12 2022-11-30 Shanghai Pharmaexplorer Co., Ltd. Monoklonaler antikörper gegen menschliches interleukin 5 (il-5) und dessen verwendung
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
BR112022000581A2 (pt) 2019-08-05 2022-03-03 Regeneron Pharma Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
EP4162257A1 (de) 2020-06-04 2023-04-12 Amgen Inc. Beurteilung von reinigungsvorgängen eines biotherapeutischen herstellungsverfahrens
CN114075282B (zh) * 2020-08-20 2024-01-02 南京融捷康生物科技有限公司 Il-5的结合分子及其制备方法和应用
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267779A3 (de) 1986-11-10 1990-01-17 Schering Biotech Corporation Menschlicher pleitroper Immunfaktor und dessen Muteine
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR960002183B1 (ko) * 1988-11-03 1996-02-13 쉐링 코포레이션 호산구증다증 억제또는 경감을 위한 약제학적 조성물
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1993016184A1 (en) * 1992-02-06 1993-08-19 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5625125A (en) * 1994-08-09 1997-04-29 Dnx Biotherapeutics Phospholipase A2 expressing transgenic animals
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
BR9510499B1 (pt) 1994-12-23 2009-05-05 antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
KR100479146B1 (ko) 1995-04-21 2005-05-16 셀 제네시스, 인코포레이티드 큰게놈dna결실유발법
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999045031A2 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CN1328571B (zh) 1998-12-23 2016-08-31 辉瑞大药厂 抗ctla-4的人单克隆抗体
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP1527100B1 (de) * 2002-03-29 2009-07-01 Schering Corporation Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen

Also Published As

Publication number Publication date
JP2005530490A (ja) 2005-10-13
EP1527100A2 (de) 2005-05-04
SI1527100T1 (sl) 2009-12-31
US20070025994A1 (en) 2007-02-01
DE60328195D1 (de) 2009-08-13
EP1527100A4 (de) 2006-06-14
CN1326879C (zh) 2007-07-18
US7422742B2 (en) 2008-09-09
AU2003220525A1 (en) 2003-10-20
US20030194404A1 (en) 2003-10-16
ES2327830T3 (es) 2009-11-04
US7141653B2 (en) 2006-11-28
CA2479927A1 (en) 2003-10-16
DK1527100T3 (da) 2009-09-07
JP2010011874A (ja) 2010-01-21
PT1527100E (pt) 2009-08-25
HK1070907A1 (en) 2005-06-30
MXPA04009418A (es) 2005-06-08
WO2003085089A2 (en) 2003-10-16
AU2003220525A8 (en) 2003-10-20
EP1527100B1 (de) 2009-07-01
CY1109423T1 (el) 2014-08-13
CN1656122A (zh) 2005-08-17
WO2003085089A3 (en) 2005-03-10
CA2479927C (en) 2013-03-12

Similar Documents

Publication Publication Date Title
ATE435239T1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
MY140862A (en) ANTIBODIES TO MAdCAM
AP2072A (en) Antibodies to insulin-like growth factor I receptor
TNSN06080A1 (en) Antibodies to m-csf
AP1918A (en) Antibodies to CD40
TNSN07394A1 (en) Antibodies to myostatin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1527100

Country of ref document: EP